

Salicylate choline

Chemical Properties

CAS No. :	2016-36-6
Formula:	C12H19NO4
Molecular Weight:	241.29
Storage:	Powder: -20°C for 3 years In solvent: -80°C for 1 year Actual storage temperature shall be subject to the COA.

Biological Description

Description	Salicylate choline is a derivative of Aspirin (acetylsalicylic acid) and is orally active. It significantly reduces the levels of IL-1 β , IL-6, TNF- α , and IL-10 in cells. By inducing S phase cell cycle arrest and impairing DNA damage repair, salicylate choline enhances the antitumor activity of the CRM1 inhibitor Selinexor (KPT-330). When combined with Selinexor, salicylate choline demonstrates excellent antitumor efficacy in mouse xenograft models with JeKo-1 cells. It is applicable in the research of rheumatism, inflammation, and cancer.
In vitro	Salicylate choline significantly reduces levels of IL-1 β , IL-6, TNF- α , and IL-10 in HGF-1 cells after 24 hours. In combination with Selinexor (KPT-330), Salicylate choline (2-3 mM, 48-72 hours) exhibits strong antiproliferative activity against hematologic malignancy cells, including MCL (JeKo-1, Mino), TCL (SR-786, Karpas-299), DLBCL (OCI-Ly1, OCI-Ly3, OCI-Ly19, SU-DHL-6, RPMI), MM (U266, OPM2, Xg1, KMS2), WM (BCWM, MWCL), ALL (RPCI, CRL-1783), and solid tumor cells such as pancreatic cancer (Panc-1, L3.6pl), non-small cell lung cancer (H460, A549, HCC827), small cell lung cancer (H1048), sarcoma (Fuji, SW872), and breast cancer (Hs 578T, BT-474, BT-20, MCF7). Moreover, Salicylate choline (3 mM, 24 hours) together with Selinexor significantly downregulates Rad51 and thymidylate synthase (TYMS) expression and increases γ -H2AX levels, a marker of DNA damage, in JeKo-1 cells. Additionally, Salicylate choline (3 mM, 24-48 hours) in conjunction with Selinexor after double thymidine block release significantly inhibits the expression of G2/M phase-related proteins (PLK1, Bub1b, Aurora A) in OCI-Ly1 cells (DLBCL).
In vivo	In a xenograft model using male mice implanted with JeKo-1 cells, salicylate choline (500 mg/kg, oral administration, for 6 consecutive days each week over 26 days) in combination with Selinexor exhibited remarkable anti-tumor efficacy.

Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	4.1444 mL	20.722 mL	41.4439 mL
5 mM	0.8289 mL	4.1444 mL	8.2888 mL
10 mM	0.4144 mL	2.0722 mL	4.1444 mL
50 mM	0.0829 mL	0.4144 mL	0.8289 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins

This product is for Research Use Only · Not for Human or Veterinary or Therapeutic Use

Tel:781-999-4286 E_mail:info@targetmol.com Address:34 Washington Street,Wellesley Hills,MA 02481